Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-FLU: High-Dose vs Adjuvanted Influenza Vaccine in Transplant Recipients
NCT03699839Phase 3Completed
- Sponsor
- Oriol Health Care
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of influenza virus vaccine, split virion and Fluzone Trivalent in influenza (3 arms), sponsored by Oriol Health Care. Primary endpoint: Vaccine response rate at 28 days. Started Oct 2018; status: completed.
02
Drugs
influenza virus vaccine, split virionFluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03699839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699839.